CRX-526

• CAT Number: I025226
• CAS Number: 245515-64-4
• Molecular Formula: C69H127N2O19P
• Molecular Weight: 1319.7438
• Purity: 98%
• Synonyms: CRX-526; CRX 526; CRX526
• Solubility: Soluble in DMSO
• Appearance: unknown
• Storage: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
• IUPAC Name: (2S)-2-[[(3R)-3-hexanoyloxytetradecanoyl]amino]-3-[(2R,3R,4R,5S,6R)-3-[[(3R)-3-hexanoyloxytetradecanoyl]amino]-4-[(3R)-3-hexanoyloxytetradecanoyl]oxy-6-(hydroxymethyl)-5-phosphonooxyoxan-2-yl]oxypropanoic acid
• InChI: InChI=1S/C69H127N2O19P/c1-7-13-19-22-25-28-31-34-40-43-54(85-61(75)46-37-16-10-4)49-59(73)70-57(68(79)80)53-84-69-65(71-60(74)50-55(86-62(76)47-38-17-11-5)44-41-35-32-29-26-23-20-14-8-2)67(66(58(52-72)88-69)90-91(81,82)83)89-64(78)51-56(87-63(77)48-39-18-12-6)45-42-36-33-30-27-24-21-15-9-3/h54-58,65-67,69,72H,7-53H2,1-6H3,(H,70,73)(H,71,74)(H,79,80)(H2,81,82,83)/t54-,55-,56-,57+,58-,65-,66-,67-,69-/m1/s1
• InChIKey: PRIXXGNJDNLMBH-DPGPRPECSA-N
• SMILES: O=C(O)[C@@H](NC(C[C@H](OC(CCCCC)=O)CCCCCCCCCCC)=O)CO[C@@H]1O[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(C[C@H](OC(CCCCC)=O)CCCCCCCCCCC)=O)[C@H]1NC(C[C@H](OC(CCCCC)=O)CCCCCCCCCCC)=O

CRX-526 is a TLR4 antagonist, protecting against advanced diabetic nephropathy.

Reference

1: Wang H, Gu J, Hou X, Chen J, Yang N, Liu Y, Wang G, Du M, Qiu H, Luo Y, Jiang Z, Feng L. Anti-inflammatory effect of miltirone on inflammatory bowel disease via TLR4/NF-κB/IQGAP2 signaling pathway. Biomed Pharmacother. 2017 Jan;85:531-540. doi: 10.1016/j.biopha.2016.11.061. Epub 2016 Nov 27. PubMed PMID: 27903427.
2: Zhou J, Soltow M, Zimmermann K, Pavlovic D, Johnston B, Lehmann C. Experimental TLR4 inhibition improves intestinal microcirculation in endotoxemic rats. Microvasc Res. 2015 Sep;101:33-7. doi: 10.1016/j.mvr.2015.06.004. Epub 2015 Jun 24. PubMed PMID: 26116862.
3: Huang HY, Zhang ZJ, Cao CB, Wang N, Liu FF, Peng JQ, Ren XJ, Qian J. The TLR4/NF-κB signaling pathway mediates the growth of colon cancer. Eur Rev Med Pharmacol Sci. 2014;18(24):3834-43. PubMed PMID: 25555874.
4: Lin M, Yiu WH, Li RX, Wu HJ, Wong DW, Chan LY, Leung JC, Lai KN, Tang SC. The TLR4 antagonist CRX-526 protects against advanced diabetic nephropathy. Kidney Int. 2013 May;83(5):887-900. doi: 10.1038/ki.2013.11. Epub 2013 Feb 20. PubMed PMID: 23423259.
5: Zanotti G, Casiraghi M, Abano JB, Tatreau JR, Sevala M, Berlin H, Smyth S, Funkhouser WK, Burridge K, Randell SH, Egan TM. Novel critical role of Toll-like receptor 4 in lung ischemia-reperfusion injury and edema. Am J Physiol Lung Cell Mol Physiol. 2009 Jul;297(1):L52-63. doi: 10.1152/ajplung.90406.2008. Epub 2009 Apr 17. PubMed PMID: 19376887; PubMed Central PMCID: PMC2711808.
6: Bazin HG, Murray TJ, Bowen WS, Mozaffarian A, Fling SP, Bess LS, Livesay MT, Arnold JS, Johnson CL, Ryter KT, Cluff CW, Evans JT, Johnson DA. The ‘Ethereal’ nature of TLR4 agonism and antagonism in the AGP class of lipid A mimetics. Bioorg Med Chem Lett. 2008 Oct 15;18(20):5350-4. doi: 10.1016/j.bmcl.2008.09.060. Epub 2008 Sep 19. PubMed PMID: 18835160.
7: Fort MM, Mozaffarian A, Stöver AG, Correia Jda S, Johnson DA, Crane RT, Ulevitch RJ, Persing DH, Bielefeldt-Ohmann H, Probst P, Jeffery E, Fling SP, Hershberg RM. A synthetic TLR4 antagonist has anti-inflammatory effects in two murine models of inflammatory bowel disease. J Immunol. 2005 May 15;174(10):6416-23. PubMed PMID: 15879143.